Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
about
Current trends and intricacies in the management of HIV-associated pulmonary tuberculosisNew Antiretroviral Treatment for HIVEnding the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.Self-Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant Women under Option B+: A Prospective StudyCost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyPlasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.Drug interactions between hormonal contraceptives and antiretrovirals.HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.How can we achieve universal access to low-cost treatment for HIV?Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.Dealing with the spiralling price of medicines: issues and solutions.Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America.High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily
P2860
Q28069032-69F34C38-2482-45B9-9BEF-FDC2A7AE8977Q28069829-2BE46FD5-EC8F-4031-AD46-1097891C35AFQ28073723-D7368CB6-B61C-4F9D-BA10-9D96A7C3536FQ33765196-7E54361A-62B8-438A-A4C9-B1F8D38FB223Q36167659-CC54099C-3074-4727-B82D-BEFD5CA27F70Q36801543-EE04766B-014E-4820-82FF-595373D660E5Q37026878-7994E244-19D2-4FF4-B3E3-FA85B4845533Q37519804-B49A8C82-F96D-4DD5-8131-3A564B9027A5Q37538760-639321B8-B638-4442-9033-11014E0F4BABQ37706150-790ED557-6101-4D74-8998-0C79C7F621EFQ37735345-1F3DB860-B515-4DC0-B632-CADA2840BA36Q38682077-19671D78-E29D-472C-80CE-131D40D94CCAQ38855121-5888A770-FF26-4922-8DED-F236CA674D6BQ38954109-A81AA92A-194A-4CB4-91DB-97A13C1BD35AQ38957969-BF334FA5-66A9-40AD-93CA-FC17626058B1Q38987587-73149C71-9A33-462C-8910-BA8BEA8545FBQ38997526-FAAFE5B7-799E-464F-920B-479CAA4E9612Q40050910-1FEA7495-4F99-4810-8A0A-422901D36AF0Q40118824-DAD9F3DC-C269-4330-8630-CFB631EC4EC4Q40707619-98975375-97A2-40F2-8F05-6C8BC4FF64FBQ42380889-F5AACD90-D7BE-4842-8A98-C2BF1764CED0Q46460183-001448E6-2C5D-4C29-9F97-07C2A20C1F11Q47117336-A16A5FC5-B400-42E3-B8A8-06127CB8DBA0Q47350202-29D70E7F-AF7A-42B8-B735-1CB0E2D1A0C3Q50080930-8D810F4B-5424-4028-A4BA-D9A55A0BDAF3Q52655906-E472D9DB-E336-4633-A0CF-E087AD93F1C7Q52661543-C5DF0A97-0576-4677-8AB3-2461C5BEF322Q56910903-773BFBF2-4A7A-4E25-8F7A-25911638AAE3
P2860
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and safety of efavire ...... non-inferiority ENCORE1 study.
@ast
Efficacy and safety of efavire ...... non-inferiority ENCORE1 study.
@en
type
label
Efficacy and safety of efavire ...... non-inferiority ENCORE1 study.
@ast
Efficacy and safety of efavire ...... non-inferiority ENCORE1 study.
@en
prefLabel
Efficacy and safety of efavire ...... non-inferiority ENCORE1 study.
@ast
Efficacy and safety of efavire ...... non-inferiority ENCORE1 study.
@en
P2093
P1476
Efficacy and safety of efavire ...... non-inferiority ENCORE1 study.
@en
P2093
Alan Winston
Brenda Crabtree-Ramirez
David A Cooper
Dianne Carey
ENCORE1 Study Group
Heiko Jessen
Lerato Mohapi
Man-Po Lee
Marcelo Losso
Praphan Phanupak
P304
P356
10.1016/S1473-3099(15)70060-5
P577
2015-04-12T00:00:00Z